Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15586081 | 0.84 | F10 (0.40) | F10 | |
| SCHEMBL12685102 | 0.83 | — | — | |
| SCHEMBL15773956 | 0.81 | F10 (0.41) | F10DGAT1HRH1HRH4 | |
| SCHEMBL19521621 | 0.80 | F10 (0.38) | F10DGAT1TSHRKDM1ANPY5R | |
| SCHEMBL19087011 | 0.80 | NPY5R (0.41) | F10DGAT1TSHRKDM1ANPY5R | |
| SCHEMBL17571952 | 0.80 | NPY5R (0.45) | F10DGAT1TSHRKDM1ANPY5R | |
| SCHEMBL17571954 | 0.78 | NPY5R (0.47) | F10DGAT1TSHRKDM1ANPY5R | |
| SCHEMBL15747143 | 0.77 | TSHR (0.36) | F10DGAT1TSHRKDM1ANPY5R | |
| SCHEMBL15586080 | 0.72 | F10 (0.35) | F10TSHRKDM1ANPY5RHRH1 | |
| SCHEMBL22693554 | 0.70 | TSHR (0.38) | F10TSHRKDM1AHRH1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014082379-A9 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-02-25 | — | — | WO | disclosed |